TY - JOUR
T1 - SPECT/multislice low-dose CT
T2 - A clinically relevant constituent in the imaging algorithm of nononcologic patients referred for bone scintigraphy
AU - Even-Sapir, Einat
AU - Flusser, Gideon
AU - Lerman, Hedva
AU - Lievshitz, Gennady
AU - Metser, Ur
PY - 2007/2/1
Y1 - 2007/2/1
N2 - The purpose of this prospective study was to assess the role of SPECT/multislice low-dose (Msl) CT as a constituent in the imaging algorithm of nononcologic patients referred for 99mTc-methylene diphosphonate bone scintigraphy (BS). Methods: SPECT/CT was performed using a novel hybrid system, which incorporates a γ-camera and a multislice low-dose CT, on 76 consecutive nononcologic patients with nonspecific scintigraphic findings, which required further correlation with morphologic data. Results: SPECT/MslCT was of added clinical value in 89% of the patients. Characterizing scintigraphic lesions by their morphologic appearance, SPECT/MslCT reached a final diagnosis in 49 of 85 (58%) nonspecific scintigraphic bone lesions found in 59% (45/76) of patients, obviating the need to perform additional imaging. In another 30% of patients (23/76), SPECT/MslCT data optimized the patients' imaging algorithm as the performance of a full-dose CT, MRI, or labeled-leukocyte scintigraphy as the next imaging was based on its findings combined with the patient's clinical presentation. Conclusion: SPECT/MslCT is a clinically relevant constituent in the imaging algorithm of nononcologic patients referred for BS.
AB - The purpose of this prospective study was to assess the role of SPECT/multislice low-dose (Msl) CT as a constituent in the imaging algorithm of nononcologic patients referred for 99mTc-methylene diphosphonate bone scintigraphy (BS). Methods: SPECT/CT was performed using a novel hybrid system, which incorporates a γ-camera and a multislice low-dose CT, on 76 consecutive nononcologic patients with nonspecific scintigraphic findings, which required further correlation with morphologic data. Results: SPECT/MslCT was of added clinical value in 89% of the patients. Characterizing scintigraphic lesions by their morphologic appearance, SPECT/MslCT reached a final diagnosis in 49 of 85 (58%) nonspecific scintigraphic bone lesions found in 59% (45/76) of patients, obviating the need to perform additional imaging. In another 30% of patients (23/76), SPECT/MslCT data optimized the patients' imaging algorithm as the performance of a full-dose CT, MRI, or labeled-leukocyte scintigraphy as the next imaging was based on its findings combined with the patient's clinical presentation. Conclusion: SPECT/MslCT is a clinically relevant constituent in the imaging algorithm of nononcologic patients referred for BS.
KW - Bone
KW - CT
KW - Fusion
KW - SPECT
KW - SPECT/CT
UR - http://www.scopus.com/inward/record.url?scp=34047196313&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17268031
AN - SCOPUS:34047196313
SN - 0161-5505
VL - 48
SP - 319
EP - 324
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 2
ER -